Sending Office: Honorable Andy Biggs
***Referenced in President Trump’s State of the Union Address!***
Current Cosponsors: Fitzpatrick, Cramer, Grothman, Messer, Pittenger, Stewart, Lance, Olson, Lamborn, Carson, McSally, Yoho, Rohrabacher, Duncan (SC), Lewis (MN), Barr, Bridenstine, Gohmert, Banks, Smucker, Brat, Sensenbrenner, Schweikert, Marino, Rokita,
Issa, Griffith, Gaetz, Hensarling, Bacon, Posey, Abraham, Sinema, Graves, Tipton, Arrington, Correa, Faso, Polis, Poe, Hartzler, Comstock, Gosar, Meadows, Brooks, Rothfus, Allen, Harris, Norman, Yoder, LaMalfa, Chabot, Roe, Marshall, Barletta, Hill, Budd,
Tenney, Labrador, Hice, Garrett, Thompson, Walberg, King (NY), Weber, DesJarlais, Mooney, Higgins, Gallagher, Gibbs, Johnson (LA), Blum, Jordan, Perry, Sanford, Ratcliffe, Luetkemeyer
Cosponsor the Right to Try Act
(H.R. 878) and Help Us to Get this Legislation Across the Finish Line!
I am writing to invite you to support the Right to Try Act (H.R. 878), a House companion bill to legislation that passed the Senate by unanimous consent last August.
Right to Try would allow terminally ill patients who have no other options left to receive drugs that have passed the Food and Drug Administration’s basic safety testing, but which have not been fully approved. For those who don’t have time to wait years
for the full FDA approval process to conclude, or who may not qualify for a clinical trial, Right to Try grants patients the freedom to try drug therapies in situations in which the potential benefits could outweigh the risks. In essence, it gives patients
the option of trying to save their own lives.
Right to Try is already law in 38 states. This bill would simply ensure that the federal government, including the FDA, does not interfere with these state laws. The Right to Try Act includes the following safeguards:
- It applies only to terminally ill patients and does not undo the current FDA approval process.
- It applies only to drugs that have gone through FDA Phase I (safety) testing.
- It requires physician certification that other options are exhausted or not available, thereby maintaining incentives for patients to seek out and join clinical trials.
- It ensures adverse outcomes are not held against pending pharmaceutical applications for FDA approval, thereby preventing drug companies from being discouraged to participate.
- It precludes patients, doctors, and manufacturers from assuming any additional liability under this act.
If you have any questions or would like to sign on as a cosponsor, please contact Jeff Kuckuck in my office at firstname.lastname@example.org.
Member of Congress
e-Dear Colleague version 2.0